Cullinan Therapeutics Doses First Patient in Phase 2 AML Study

Key Facts

1Cullinan Therapeutics announced the first patient has been dosed in its pivotal Phase 2 study of CLN-049.

Cullinan Therapeutics announced the first patient has been dosed in its pivotal Phase 2 study of CLN-049. The company said in a statement via GlobeNewswire that the trial targets patients with relapsed or refractory acute myeloid leukemia (AML), an aggressive form of blood cancer.

The study aims to evaluate the efficacy of CLN-049, a novel FLT3 T cell engager, as a potential treatment for the disease. CGEM closed at $15.63 on October 7, 2026, with the stock trading between a low of $15.47 and a high of $16.46 during that session.